Omeros Corporation
Omeros Corporation (Nasdaq: OMER) is a commercial-stage biotechnology company that discovers and develops protein and small-molecule therapeutics, with programs focused on complement-mediated diseases, cancer, and addictive or compulsive disorders. Its commercial product, YARTEMLEA, is an antibody that inhibits MASP-2… From the company’s description.
In fiscal 2025, Omeros Corporation reported a net loss of $3.35M. Operations used $116.09M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Omeros Corporation does
In the company’s own words
Omeros Corporation (Nasdaq: OMER) is a commercial-stage biotechnology company that discovers and develops protein and small-molecule therapeutics, with programs focused on complement-mediated diseases, cancer, and addictive or compulsive disorders. Its commercial product, YARTEMLEA, is an antibody that inhibits MASP-2 in the lectin pathway of complement and is approved in the United States to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and children aged two years and older. U.S. sales began in January 2026, with commercialization focused on transplant centers. Omeros also develops narsoplimab for other potential uses, a long-acting MASP-2 antibody, a PDE7 inhibitor for cocaine use disorder and movement disorders, an oncology candidate for acute myeloid leukemia, and targeted complement-activating therapies for infectious diseases. In 2025, it transferred exclusive global development and commercialization rights to its lead MASP-3 antibody, zaltenibart, to Novo Nordisk, while retaining rights to related small-molecule programs. YARTEMLEA and YARTEMLEAssist are its principal commercial brands.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 1285819
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Omeros Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Omeros Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Omeros Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Omeros Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Omeros Corporation's last four quarterly filings that the numbers alone won't show?”